Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | NAMPT | P43490 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643434 | 0.88 | ADRA2B (0.70) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL6646888 | 0.88 | ADRA2B (0.66) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL6645605 | 0.86 | GAA (0.75) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL6838344 | 0.86 | ALDH1A1 (0.75) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL6843369 | 0.86 | ADRA2B (0.66) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL7081755 | 0.85 | ADRA2B (0.60) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL6669539 | 0.83 | KMT2A (0.60) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL6644025 | 0.82 | ADRA2B (0.69) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL6843456 | 0.82 | ADRA2B (0.58) | ADRA2BALDH1A1CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL6644703 | 0.81 | ADRA2B (0.64) | ADRA2BALDH1A1GAACYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767909-B2 | CARDIOVASCULAR DISORDERS; VASOCONSTRICTION | OY JUVANTIA PHARMA LTD. (FI) | 2004-07-27 | — | — | US | disclosed |
| US-20030073710-A1 | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | OY JUVANTIA PHARMA LTD (FI) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073710-A1 | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | ADRB2, ADRB3, ADRB1 | ADRA2B 6/4885NAMPT 3188/4885ALDH1A1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.